Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans

Journal of Medical Virology

Volumn 80, Issue 11, 2008, Pages 1992-1996

  Tang, Julian W ^a   Ngai, Karry L K ^a   Chan, Paul K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Ferret; Hemagglutination inhibition; Hemagglutinin; Human; Microneutralization; Mouse; Neuraminidase

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOREACTIVITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MALE; NORMAL HUMAN; PILOT STUDY;

ADULT; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PILOT PROJECTS;

ANIMALIA; AVES; INFLUENZA A VIRUS; MUSTELA; ORTHOMYXOVIRIDAE;

EID: 54749127820     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21321     Document Type: Article

References (38)

1. Andreasen V, Viboud C, Simonsen L. 2008. Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: Implications for pandemic control strategies. J Infect Dis 197:270-278.
2. Bartlett JG, Borio L. 2008. Healthcare epidemiology: The current status of planning for pandemic influenza and implications for health care planning in the United States. Clin Infect Dis 46:919-925.
3. Beigel J, Bray M. 2008. Current and future antiviral therapy of severe seasonal and avian influenza. Antivir Res 78:91-102.
4. Blomqvist S, Bruu AL, Stenvik M, Hovi T. 2003. Characterization of a recombinant type 3/type 2 polio virus isolated from a healthy vaccine and containing a chimeric capsid protein VP1. J Gen Virol 84:573-580.
5. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. 2006. Epidemic influenza and vitamin D. Epidemiol Infect 134:1129-1140.
6. Cannell JJ, Zasloff M, Garland CF, Scragg R, Giovannucci E. 2008. On the epidemiology of influenza. Virol J 5:29.
7. Carrat F, Lavenu A. 2006. Heterosubtypic immunity to influenza: Right hypothesis, wrong comparison. J Infect Dis 193:1613.
8. Davey VJ, Glass RJ. 2008. Rescinding community mitigation strategies in an influenza pandemic. Emerg Infect Dis 14:365-372.
9. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358:2573-2584.
10. Epstein SL. 2006. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: An experiment of nature. J Infect Dis 193:49-53.
11. Gillim-Ross L, Subbarao K. 2007. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses? PLoS Med 4:e91.
12. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, Agrati C, Squarcione S, Ippolito G, Puro V, Capobianchi MR, Poccia F. 2008. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14:121-128.
13. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194:159-167.
14. Hampson AW. 2006. Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194:143-145.
15. Jameson J, Cruz J, Terajima M, Ennis FA. 1999. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162:7578-7583.
16. Kilbourne ED. 2006. Influenza immunity: New insights from old studies. J Infect Dis 193:7-8.
17. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2008. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82:5161-5166.
18. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 13:8026.
19. Maher JA, DeStefano J. 2004. The ferret: An animal model to study influenza virus. Lab Anim (NY) 33:50-53.
20. Maines TR, Chen LM, Matsuoka Y, Chen H, Rowe T, Ortin J, Falcón A, Nguyen TH, Mai le Q, Sedyaningsih ER, Harun S, Tumpey TM, Donis RO, Cox NJ, Subbarao K, Katz JM. 2006. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci USA 103:12121-12126.
21. Meltzer MI. 2008. Pandemic influenza, reopening schools, and returning to work. Emerg Infect Dis 14:509-510.
22. Monto AS, Whitley RJ. 2008. Seasonal and pandemic influenza: A 2007 update on challenges and solutions. Clin Infect Dis 46:1024-1031.
23. Nicholson KG, Wood JM, Zambon M. 2003. Influenza. Lancet 362:1733-1745.
24. Oshitani H, Kamigaki T, Suzuki A. 2008. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 14:875-880.
25. Paranthaman K, Conlon CP, Parker C, McCarthy N. 2008. Resource allocation during an influenza pandemic. Emerg Infect Dis 14:520-522.
26. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. 2008. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 180:1758-1768.
27. Saito R, Suzuki Y, Li D, Zaraket H, Sato I, Masaki H, Kawashima T, Hibi S, Sano Y, Shobugawa Y, Oguma T, Suzuki H. 2008. Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006-2007 influenza season in Japan. J Infect Dis 197:630-632.
28. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4:e59.
29. Seo SH, Peiris M, Webster RG. 2002. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76:4886-4890.
30. Smallman-Raynor M, Cliff AD. 2007. Avian influenza A (H5N1) age distribution in humans. Emerg Infect Dis 13:510-512.
31. Smith W, Andrewes CH, Laidlaw PP. 1933. A virus obtained from influenza patients. Lancet 222:66-68.
32. Tang JW, Ngai KL, Wong JC, Lam WY, Chan PK. 2008. Emergence of adamantane-resistant influenza A(H3N2) viruses in Hong Kong between 1997 and 2006. J Med Virol 80:895-901.
33. Tang JW. 2008. Pandemic influenza forecasting: Does past performance indicate future performance? Am J Infect Control (available on journal website, June 9, 2008 at: http://journals.elsevierhealth.com/periodicals/ymic/inpress). (DOI: 10.1016.jajic.2007.12.007).
34. Tang JW. 2005a. Influenza vaccine cross-protection: Request for information. ProMED-mail. 19 Oct: 20051019.3051. http://www.promedmail.org.
35. Tang JW. 2005b. Influenza vaccine cross-protection (2). ProMED-mail. ; 26 Oct: 20051026.3121. http://www.promedmail.org.
36. World Health Organization. 2002. WHO manual on animal influenza diagnosis and surveillance. Geneva, World Health Organization (document WHO/CDS/CSR/NCS /2002.5) 28-39.
37. World Health Organization Global Influenza Program Surveillance Network. 2005. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11:1515-1521.
38. Wright PF. 2008. Vaccine preparedness - Are we ready for the next influenza pandemic? N Engl J Med 358:2540-2543.